# A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

> **NCT02301117** · PHASE1 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TAS-102

## Key facts

- **NCT ID:** NCT02301117
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-06-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02301117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02301117, "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02301117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*